首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

2050743

比美珠單抗市場：依適應症、年齡層、性別、最終用戶、通路和地區分類

Bimekizumab Market, By Indication, By Age Group, By Gender, By End User, By Distribution Channel, By Geography

出版日期: 2026年04月01日 | 出版商:

Coherent Market Insights | 英文 168 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，bimekizumab 市值將達到 18.3 億美元，到 2033 年將達到 68.5 億美元。預計從 2026 年到 2033 年，其複合年成長率將達到 20.7%。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	18.3億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	20.70%	2033年市場規模預測：	68.5億美元

全球比美珠單抗市場是生物製藥行業中一個快速發展的細分市場，其核心是新型單株抗體療法，該療法能夠選擇性地抑制白細胞介素-17A和白細胞介素-17F兩種細胞激素。作為一種創新免疫調節劑，比美珠單抗正逐漸成為治療多種自體免疫發炎疾病（尤其是僵直性脊椎炎、乾癬性關節炎及其他相關發炎性疾病）的極具前景的治療選擇。這種對IL-17A/F的雙重抑制機制使比美珠單抗區別於現有的IL-17抑制劑，並有望提高治療效果，改善患者預後。

市場成長的主要驅動力是自體免疫疾病在全球範圍內的日益普遍、人們對先進生技藥品療法的認知不斷提高以及對標靶免疫療法解決方案需求的不斷成長。在關鍵醫藥市場獲得監管部門的核准，已使bimekizumab成為生技藥品治療領域的重要競爭者。製藥業對精準醫療和個人化治療方案的持續關注，進一步加速了市場對該療法的接受度。與傳統的單標靶治療相比，醫療專業人員越來越認知到雙細胞激素抑制劑療法的潛在優勢，這有助於擴大臨床應用範圍，並提高其在尋求有效長期控制慢性發炎性疾病的各類患者群體中的市場滲透率。

市場動態

全球比美珠單抗市場正經歷強勁成長，其主要促進因素包括乾癬、乾癬性關節炎和僵直性脊椎炎自體免疫疾病在全球日益普遍。這些疾病影響著數百萬患者，他們都在尋求有效的治療方法方案。臨床試驗中展現出的卓越療效，尤其是其雙重IL-17A/F抑制機制，與單靶點競爭藥物相比，顯著提升了治療效果，是推動市場成長的主要因素。此外，醫療保健支出不斷成長以及生技藥品的日益普及也促進了市場發展。醫療專業人員對先進免疫調節療法的認知不斷提高，診斷能力的不斷增強，以及已開發市場有利的報銷政策，都為患者提供了便利。

然而，生技藥品市場成長面臨許多限制因素，包括其極高的成本，這限制了其可及性，尤其是在醫療預算有限的新興國家；嚴格的監管核准流程需要大量的臨床證據；免疫抑制可能帶來的安全隱患，例如感染疾病風險增加；以及來自現有IL-17抑製劑和其他生技藥品的激烈競爭。單株抗體生產的複雜性和供應鏈挑戰也構成營運方面的限制因素。

儘管如此，隨著生物製劑在自體免疫疾病領域的應用（目前正在進行臨床試驗）、在新興市場（醫療基礎設施正在發展中）的滲透率不斷提高、聯合治療的研發（有望改善治療效果）、對個性化醫療方法的日益關注，以及專利到期後生物類似藥的開發，都湧現出巨大的機遇。這些因素可望提高市場可近性和可負擔性，使更多患者受益。

本研究的關鍵特徵

本研究確定了各個細分市場的潛在商機，並說明了該市場具有吸引力的投資提案矩陣。
此外，本研究還深入分析了市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域展望以及主要參與者採取的競爭策略。
本研究根據以下參數創建了全球比美珠單抗市場主要公司的概況：公司亮點、產品系列、主要特徵、財務表現和策略。
本次調查涵蓋的主要公司包括 UCB。
透過利用本報告中的見解，企業行銷負責人和經營團隊將能夠就未來的產品發布、產品升級、市場擴張和行銷策略做出明智的決策。
全球比美珠單抗市場報告的目標受群眾外包括該行業的各類相關人員，包括投資者、供應商、產品製造商、經銷商、新參與企業和金融分析師。
相關人員可以利用各種用於分析全球比美珠單抗市場的策略矩陣，更輕鬆地做出決策。

北美洲
- 美國
- 加拿大
拉丁美洲
- 巴西
- 阿根廷
- 墨西哥
- 其他拉丁美洲國家
歐洲
- 德國
- 英國
- 西班牙
- 法國
- 義大利
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
- ASEAN
- 其他亞太國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第10章競爭格局

第11章分析師建議

機會分析
一致的機會地圖

第12章參考文獻與調查方法

參考
調查方法
關於本公司

簡介目錄

Product Code: CMI9110

Bimekizumab Market is estimated to be valued at USD 1.83 Bn in 2026 and is expected to reach USD 6.85 Bn by 2033, growing at a compound annual growth rate (CAGR) of 20.7% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 1.83 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	20.70%	2033 Value Projection:	USD 6.85 Bn

Global bimekizumab market represents a rapidly evolving segment within biopharmaceutical industry, centered around a novel monoclonal antibody therapeutic that selectively inhibits both interleukin-17A and interleukin-17F cytokines. Bimekizumab, developed as an innovative immunomodulatory agent, has emerged as a promising treatment option for various autoimmune inflammatory conditions, particularly psoriasis, psoriatic arthritis, ankylosing spondylitis, and other related inflammatory disorders. This dual IL-17A/F inhibition mechanism distinguishes bimekizumab from existing IL-17 inhibitors, potentially offering enhanced therapeutic efficacy and improved patient outcomes.

The market's growth trajectory is primarily driven by increasing prevalence of autoimmune diseases globally, rising awareness about advanced biologic therapies, and growing demand for targeted immunotherapy solutions. Regulatory approvals across major pharmaceutical markets have positioned bimekizumab as a significant competitor in the biologic therapeutics landscape. The pharmaceutical industry's continued focus on precision medicine and personalized treatment approaches has further accelerated market adoption. Healthcare providers increasingly recognize the potential benefits of dual cytokine inhibition compared to traditional single-target therapies, contributing to expanding clinical applications and market penetration across diverse patient populations seeking effective long-term management of chronic inflammatory conditions.

Market Dynamics

The global bimekizumab market experiences robust growth driven by several key factors, including the escalating worldwide prevalence of autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis, which collectively affect millions of patients seeking effective treatment alternatives. The superior efficacy profile demonstrated in clinical trials, particularly the dual IL-17A/F inhibition mechanism that provides enhanced therapeutic outcomes compared to single-target competitors, serves as a primary market driver alongside increasing healthcare expenditure and growing adoption of biologic therapies. Rising awareness among healthcare professionals about advanced immunomodulatory treatments and expanding diagnostic capabilities contribute to market expansion, while favorable reimbursement policies in developed markets facilitate patient access.

However, market growth faces significant restraints including the exceptionally high cost of biologic therapies that limits accessibility, particularly in emerging economies with constrained healthcare budgets, stringent regulatory approval processes requiring extensive clinical evidence, potential safety concerns associated with immunosuppression including increased infection risks, and intense competition from established IL-17 inhibitors and other biologic alternatives. Manufacturing complexities and supply chain challenges for monoclonal antibodies also pose operational constraints.

Nevertheless, substantial opportunities emerge through expanding applications to additional autoimmune indications currently under clinical investigation, growing market penetration in emerging economies with improving healthcare infrastructure, development of combination therapies that could enhance treatment outcomes, increasing focus on personalized medicine approaches, and potential biosimilar development following patent expiration that could improve market accessibility and affordability for broader patient populations.

Key Features of the Study

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global bimekizumab market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key company covered as a part of this study include UCB
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global bimekizumab market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bimekizumab market

Market Segmentation

Indication Insights (Revenue, USD Bn, 2021 - 2033)
Plaque Psoriasis
Psoriatic Arthritis
Axial Spondyloarthritis
Non-radiographic axial spondyloarthritis (nraxSpA)
Other Investigational Autoimmune Indications
Age Group Insights (Revenue, USD Bn, 2021 - 2033)
Adult
Geriatric
Gender Insights (Revenue, USD Bn, 2021 - 2033)
Male
Female
End User Insights (Revenue, USD Bn, 2021 - 2033)
Hospitals
Dermatology Clinics
Rheumatology Clinics
Specialty Care Centers
Distribution Channel Insights (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
UCB

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Global Bimekizumab Market, By Indication
- Global Bimekizumab Market, By Age Group
- Global Bimekizumab Market, By Gender
- Global Bimekizumab Market, By End User
- Global Bimekizumab Market, By Distribution Channel
- Global Bimekizumab Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
Driver
Restraint
Opportunity
Impact Analysis
Key Developments
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario
Industry Trends

4. Global Bimekizumab Market, By Indication, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Plaque Psoriasis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Psoriatic Arthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Axial Spondyloarthritis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Non-radiographic axial spondyloarthritis (nraxSpA)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Other Investigational Autoimmune Indications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

5. Global Bimekizumab Market, By Age Group, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Adult
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Geriatric
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

6. Global Bimekizumab Market, By Gender, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Male
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Female
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

7. Global Bimekizumab Market, By End User, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Dermatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Rheumatology Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Specialty Care Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

8. Global Bimekizumab Market, By Distribution Channel, 2021 - 2033, (USD Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (USD Bn)

9. Global Bimekizumab Market, By Region, 2021 - 2033, Value (USD Bn)

Introduction
- Market Share (%) Analysis, 2026, 2028 & 2033, Value (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2022 - 2033, Value (USD Bn)
- Regional Trends
North America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - U.S.
  - Canada
Latin America
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Brazil
  - Argentina
  - Mexico
  - Rest of Latin America
Europe
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - Germany
  - U.K.
  - Spain
  - France
  - Italy
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
Middle East
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country, 2021 - 2033, Value (USD Bn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, By Indication, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Age Group, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Gender, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By End User, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2021 - 2033, Value (USD Bn)
- Market Size and Forecast, By Country/Region, 2021 - 2033, Value (USD Bn)
  - South Africa
  - North Africa
  - Central Africa